Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in metastatic gastric cancer (REGARD)
NCT00917384Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Primary completion
- Jul 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of ramucirumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Aug 2009; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00917384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00917384.